BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCY O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCY O
EXCERPT O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Increased O
risk O
of O
serious O
infections O
leading O
to O
hospitalization O
or O
death O
, O
including O
tuberculosis O
( O
TB O
) O
, O
bacterial O
sepsis O
, O
invasive O
fungal O
infections O
( O
such O
as O
histoplasmosis O
) O
and O
infections O
due O
to O
other O
opportunistic O
pathogens O
. O

* O
Discontinue O
REMICADE O
if O
a O
patient O
develops O
a O
serious O
infection O
. O

* O
Perform O
test O
for O
latent O
TB O
; O
if O
positive O
, O
start O
treatment O
for O
TB O
prior O
to O
starting O
REMICADE O
. O

Monitor O
all O
patients O
for O
active O
TB O
during O
treatment O
, O
even O
if O
initial O
latent O
TB O
test O
is O
negative O
. O

( O
5.1 O
) O
* O
Lymphoma O
and O
other O
malignancies O
, O
some O
fatal O
, O
have O
been O
reported O
in O
children O
and O
adolescent O
patients O
treated O
with O
tumor O
necrosis O
factor O
( O
TNF O
) O
blockers O
, O
including O
REMICADE O
. O

* O
Postmarketing O
cases O
of O
fatal O
hepatosplenic O
T-cell O
lymphoma O
( O
HSTCL O
) O
have O
been O
reported O
in O
patients O
treated O
with O
TNF O
blockers O
including O
REMICADE O
. O

Almost O
all O
had O
received O
azathioprine O
or O
6-mercaptopurine O
concomitantly O
with O
a O
TNF-blocker O
at O
or O
prior O
to O
diagnosis O
. O

The O
majority O
of O
REMICADE O
cases O
were O
reported O
in O
patients O
with O
Crohn O
's O
disease O
or O
ulcerative O
colitis O
, O
most O
of O
whom O
were O
adolescent O
or O
young O
adult O
males O
. O

( O
5.2 O
) O
SERIOUS O
INFECTIONS O
Patients O
treated O
with O
REMICADE O
( O
r O
) O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Most O
patients O
who O
developed O
these O
infections B-NonOSE_AE
were O
taking O
concomitant O
immunosuppressants B-NonOSE_AE
such O
as O
methotrexate O
or O
corticosteroids O
. O

REMICADE O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
or O
sepsis B-NonOSE_AE
. O

Reported O
infections B-OSE_Labeled_AE
include O
: O
* O
Active B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
, O
including O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
latent I-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
. O

Patients O
with O
tuberculosis B-OSE_Labeled_AE
have O
frequently O
presented O
with O
disseminated O
or O
extrapulmonary I-OSE_Labeled_AE
disease O
. O

Patients O
should O
be O
tested O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
before O
REMICADE O
use O
and O
during O
therapy.1,2 O
Treatment O
for O
latent B-Not_AE_Candidate
infection I-Not_AE_Candidate
should O
be O
initiated O
prior O
to O
REMICADE O
use O
. O

* O
Invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
histoplasmosis B-OSE_Labeled_AE
, O
coccidioidomycosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
aspergillosis B-OSE_Labeled_AE
, O
blastomycosis B-OSE_Labeled_AE
, O
and O
pneumocystosis B-OSE_Labeled_AE
. O

Patients O
with O
histoplasmosis B-OSE_Labeled_AE
or O
other O
invasive O
fungal B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
may O
present O
with O
disseminated O
, O
rather O
than O
localized O
, O
disease O
. O

Antigen B-NonOSE_AE
and O
antibody O
testing I-NonOSE_AE
for I-NonOSE_AE
histoplasmosis I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
negative I-NonOSE_AE
in O
some O
patients O
with O
active O
infection B-NonOSE_AE
. O

Empiric O
anti-fungal O
therapy O
should O
be O
considered O
in O
patients O
at O
risk O
for O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infections I-NonOSE_AE
who O
develop O
severe O
systemic O
illness B-NonOSE_AE
. O

* O
Bacterial B-OSE_Labeled_AE
, O
viral O
and O
other O
infections I-OSE_Labeled_AE
due I-OSE_Labeled_AE
to I-OSE_Labeled_AE
opportunistic I-OSE_Labeled_AE
pathogens I-OSE_Labeled_AE
, O
including O
Legionella B-OSE_Labeled_AE
and O
Listeria B-OSE_Labeled_AE
. O

The O
risks O
and O
benefits O
of O
treatment O
with O
REMICADE O
should O
be O
carefully O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
with O
chronic O
or O
recurrent O
infection B-Not_AE_Candidate
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
REMICADE O
, O
including O
the O
possible O
development O
of O
tuberculosis B-NonOSE_AE
in O
patients O
who O
tested B-Not_AE_Candidate
negative I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
therapy O
. O

MALIGNANCY O
Lymphoma B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
have O
been O
reported O
in O
children O
and O
adolescent O
patients O
treated O
with O
TNF O
blockers O
, O
including O
REMICADE O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Postmarketing O
cases O
of O
hepatosplenic B-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
lymphoma I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HSTCL I-OSE_Labeled_AE
) O
, O
a O
rare O
type O
of O
T B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
lymphoma I-NonOSE_AE
, O
have O
been O
reported O
in O
patients O
treated O
with O
TNF O
blockers O
including O
REMICADE O
. O

These O
cases O
have O
had O
a O
very O
aggressive O
disease O
course O
and O
have O
been O
fatal B-NonOSE_AE
. O

Almost O
all O
patients O
had O
received O
treatment O
with O
azathioprine O
or O
6-mercaptopurine O
concomitantly O
with O
a O
TNF-blocker O
at O
or O
prior O
to O
diagnosis O
. O

The O
majority O
of O
reported O
REMICADE O
cases O
have O
occurred O
in O
patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
and O
most O
were O
in O
adolescent O
and O
young O
adult O
males O
. O

